Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Combination in Japanese T2DM
NCT02713477Phase 1Completed
- Sponsor
- Sanofi
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lixisenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Sanofi. Primary endpoint: Plasma glucose concentrations at Day 1. Started Apr 2016; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02713477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713477.